Browsing: PI3K

The panel examines the toxicity profiles and practical considerations associated with PI3K pathway-directed therapies in hormone receptor-positive, HER2-negative metastatic breast…

As KRAS inhibitors move further into the clinic across pancreatic, lung, and colorectal cancers, attention in the field has increasingly…